TPCW
ITCI

TD Private Client Wealth’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

TD Private Client Wealth’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-102
Closed -$13.5K – 1537
2025
Q1 		$13.5K Sell
102
-45
-31% -$5.61K ﹤0.01% 984
2024
Q4 		$12.3K Buy
147
+27
+23% +$2.22K ﹤0.01% 1032
2024
Q3 		$8.78K Hold
120
– – ﹤0.01% 1068
2024
Q2 		$8.22K Buy
+120
New +$8.32K ﹤0.01% 1055
2021
Q4 		– Sell
-39
Closed -$1.45K – 1292
2021
Q3 		$1.45K Hold
39
– – ﹤0.01% 1058
2021
Q2 		$1.59K Hold
39
– – ﹤0.01% 1055
2021
Q1 		$1.32K Hold
39
– – ﹤0.01% 1032
2020
Q4 		$1.24K Hold
39
– – ﹤0.01% 993
2020
Q3 		$1K Hold
39
– – ﹤0.01% 962
2020
Q2 		$1K Hold
39
– – ﹤0.01% 958
2020
Q1 		$599 Hold
39
– – ﹤0.01% 955
2019
Q4 		$1.34K Buy
+39
New +$468 ﹤0.01% 936

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

TD Private Client Wealth's ITCI Position: Q2 2025 in Review

TD Private Client Wealth sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 102 shares — an estimated $13.5K sold.

TD Private Client Wealth first reported a position in ITCI in Q4 2019 and held it in 12 quarters. The position peaked at $13.5K in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • TD Private Client Wealth reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • TD Private Client Wealth sold 102 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $13.5K.
  • TD Private Client Wealth first reported a position in Intra-Cellular Therapies Inc. in Q4 2019 and held it in 12 quarters.
  • TD Private Client Wealth's Intra-Cellular Therapies Inc. position peaked at $13.5K in Q1 2025.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on TD Private Client Wealth's 13F filing for Q2 2025, filed 15 Jul 2025.